TL;DR
Get pet supplies delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
IDEXX Laboratories announced North American availability of mast cell tumor detection as part of its Cancer Dx Panel for dogs, which already screens for lymphoma. The test can be run using blood collected for routine wellness testing, but a positive result requires veterinary assessment and further diagnostic investigation.
IDEXX Laboratories has expanded its Cancer Dx Panel in North America to include detection of canine mast cell tumors, adding to its existing lymphoma screening. The company says the test can be run on blood collected alongside routine wellness testing, without an additional blood draw.
The screening is intended for apparently healthy dogs at increased risk of cancer, according to the announcement. IDEXX recommends it for all senior dogs aged 7 and older and for younger dogs aged 4 and older from predisposed breeds. The company names Golden Retrievers, Labrador Retrievers, Boxers and German Shepherds among the examples.
IDEXX said its panel is designed to prioritize aggressive, clinically significant tumors. The company describes the results as cancer-specific: a positive finding identifies a particular cancer signal rather than a generalized indication of cancer risk. It says a positive result should be followed by a clinical assessment and further diagnostic investigation; the screening result alone is not a diagnosis.
The company listed a price of about US$15 (about C$21) for veterinary practices when the panel is run alongside the most commonly used IDEXX Reference Laboratories wellness screening panels. The price charged to pet owners is set by individual veterinary practices. The announcement did not provide test accuracy figures or detail how results should be interpreted for individual dogs.
Adding Cancer Screening to Wellness Visits
The expansion brings a cancer screening option into a workflow that already includes routine blood collection. For practices that use the specified IDEXX wellness panels, the company says the Cancer Dx test can be added without a separate blood draw. That may make screening easier to offer during a regular visit, although whether a practice recommends or uses it will depend on its clinical judgment and each dog’s circumstances.
Mast cell tumors are among the most common canine skin tumors, according to IDEXX’s announcement. The company says its screening is aimed at more aggressive, high-grade tumors, where earlier identification may have clinical value. This is a stated design aim, not evidence in the announcement that screening improves survival or other health outcomes. For owners, a key distinction is that a positive result calls for follow-up testing rather than confirming cancer on its own.
As an affiliate, we earn on qualifying purchases.
From Lymphoma Toward Broader Screening
The new mast cell tumor detection builds on the panel’s earlier canine lymphoma screening. IDEXX presents the expansion as part of a wider plan to add screening for multiple cancers in dogs. The company says one in four dogs will face cancer in its lifetime; that figure is presented in the source announcement and is not accompanied there by a study citation or further methodological detail.
IDEXX also announced a planned addition for hemangiosarcoma, a life-threatening cancer that the company says is often discovered only after an internal tumor ruptures. Detection for that cancer is scheduled to become available to clinics across North America in December 2026. That is a future availability date, not a feature currently included in the newly expanded panel.
Test Performance and Follow-Up Details
The announcement does not report the panel’s sensitivity, specificity, false-positive rate or performance across different dog populations. It also does not explain which diagnostic procedures veterinarians may use after a positive result, or how quickly follow-up should occur. Those details matter because the company says screening results require clinical assessment and further investigation.
It is also unclear how often a negative screen could miss a tumor, whether repeat testing is recommended, and what evidence supports screening’s effect on treatment choices or health outcomes. The announcement gives a recommended age and breed-risk framework, but individual decisions remain a matter for veterinarians and pet owners.
Clinics Prepare for Later Additions
Veterinary practices in North America can now ask IDEXX about the expanded panel, its use alongside eligible wellness testing and the practice’s pricing for clients. Owners considering screening can discuss their dog’s age, breed, health history and the meaning of possible results with their veterinarian. Any positive finding should be interpreted alongside an examination and follow-up diagnostics.
The next stated expansion is hemangiosarcoma detection in December 2026, when IDEXX says it expects the feature to be available to North American clinics. The company has not provided additional performance data or a detailed rollout schedule in the source announcement.
Key Questions
What cancer detection has IDEXX added to the panel?
IDEXX added mast cell tumor detection to its Cancer Dx Panel in North America. The panel already included canine lymphoma screening.
Which dogs is the screening intended for?
IDEXX says screening is intended for apparently healthy dogs at increased risk, including all dogs aged 7 and older and dogs aged 4 and older from predisposed breeds such as Golden Retrievers, Labrador Retrievers, Boxers and German Shepherds. A veterinarian can advise whether it is appropriate for a particular dog.
Does a positive result mean a dog has cancer?
No. IDEXX says a positive result identifies a cancer-specific signal, but it should be followed by a clinical assessment and further diagnostic investigation. The announcement does not describe the result as a standalone diagnosis.
How much does the panel cost?
IDEXX lists a practice price of about US$15, or C$21, when the panel is run alongside certain commonly used IDEXX wellness screening panels. Each veterinary practice sets its own price for pet owners.
When will hemangiosarcoma detection be added?
IDEXX says hemangiosarcoma detection is planned for North American clinics in December 2026. It is not part of the mast cell tumor expansion announced as currently available.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
